JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
1687 results found
Presentation
Diasorin "The Right Test At The Right Time" Presentation
02/08/24
Investors
Press releases
DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS
25/07/17 - 21:00
Investors
Press releases
DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business
30/03/16 - 2:00
Investors
Press releases
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
Price sensitive11/04/21 - 19:47
Investors
Presentation
Diasorin to Present at Jefferies London Healthcare Conference 2024
20/11/24
Investors
Presentation
Diasorin to present at J.P. Morgan Healthcare Conference 2025
15/01/25
Investors
Press releases
Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com
24/10/23 - 15:03
Investors
Press releases
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study
09/07/20 - 7:27
Investors
Press releases
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market
01/10/20 - 7:32
Investors
Press releases
DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market
Price sensitive20/05/21 - 8:27
Investors
Press releases
DiaSorin's stocks listed in the FTSE MIB
04/12/18 - 8:00
Investors
Information Documents
Disclosure Concerning Awards of Financial Instruments to Directors, Executives and Other Employees of DiaSorin S.p.A. and its Subsidiaries
Press releases
Dividend may be distributed in June
20/12/10 - 1:00
Investors
Shareholders' meeting
Documentation for the nomination and appointment of Mrs. Fiorella Altruda as Board member
27/04/17 - 14:00
About Diasorin
Shareholders' meeting
Draft Company annual financial statements and consolidated financial statements
28/04/09 - 14:00
About Diasorin
Events
Draft Statutory Financial and Consolidated Financial Statements 2012 approval
Newsroom
Coverage
EQUITA SIM
Investors
Shareholder basis
Even Chen
About Diasorin
Coverage
EXANE BNP PARIBAS
Investors
Press releases
Execution of the project for the redefinition of the corporate structure of DiaSorin
07/06/22 - 18:06
Investors
Shareholders' meeting
Explanatory Report by the Board of Directors to the convened to vote on a motion to authorize purchases and/or sales of treasury shares
04/10/11 - 14:00
About Diasorin
Shareholders' meeting
Explanatory Report Stock Options plan 2014
23/04/14 - 14:00
About Diasorin
Shareholders' meeting
Explanatory Reports Shareholders' Meeting April 27, 2017
27/04/17 - 14:00
About Diasorin
Shareholders' meeting
Explanatory Reports Shareholders' Meeting April 28, 2016 - Extraordinary Part
28/04/16 - 14:00
About Diasorin
Shareholders' meeting
Explanatory Reports Shareholders' Meeting April 28, 2016 - Ordinary Part
28/04/16 - 14:00
About Diasorin
Shareholders' meeting
Extraordinary Shareholders' Meeting minutes April 22, 2021
22/04/21 - 14:00
About Diasorin
Shareholders' meeting
Extraordinary Shareholders' Meeting minutes April 28, 2016
28/04/16 - 14:00
About Diasorin
Shareholders' meeting
Extraordinary Shareholders' Meeting minutes October 4, 2021
04/10/21 - 14:00
About Diasorin
Press releases
FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay
07/09/20 - 18:22
Investors
Press releases
FDA approves 1,25 Vitamin D in the US market
16/12/14 - 1:00
Investors
Press releases
FDA approves the Aldosterone assay
17/04/13 - 2:00
Investors
Press releases
FDA approves the LIAISON XL
26/01/11 - 1:00
Investors
Press releases
FDA clearance for 25 OH Vitamin D on LIAISON
02/02/12 - 1:00
Investors
Press releases
FDA clearance to five LIAISON products
08/01/09 - 1:00
Investors
Press releases
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l.
04/04/22 - 18:12
Investors
Shareholder basis
Finde SS
About Diasorin
Presentation
FY 2011 Results Presentation
09/03/12
Investors
Presentation
FY 2012 Results Presentation
08/03/13
Investors
Presentation
FY 2013 Results Presentation
06/03/14
Investors
Presentation
FY 2014 Results Presentation
30/03/15
Investors
Results
FY 2014 Results Presentation
Investors
Presentation
FY 2015 Results Presentation
17/03/16
Investors
Results
FY 2015 Results Presentation
Investors
Presentation
FY 2016 Results Presentation
08/03/17
Investors
Results
FY 2016 Results Presentation
Investors
Presentation
FY 2017 Results Presentation
07/03/18
Investors
Results
FY 2017 Results Presentation
Investors
Presentation
FY 2018 Results Presentation
14/03/19
Investors
Results
FY 2018 Results Presentation
Investors
Presentation
FY 2019 Results Presentation
11/03/20
Investors
Results
FY 2019 Results Presentation
Investors
Presentation
FY 2020 Results Presentation
11/03/21
Investors
Results
FY 2020 Results Presentation
Investors
Presentation
FY 2021 Results Presentation
16/03/22
Investors
Results
FY 2021 Results Presentation
Investors
Presentation
FY 2022 Results Presentation
27/03/23
Investors
Results
FY 2022 Results Presentation
Investors
Events
Goldman Sachs 6th Annual European Medtech and Healthcare Services Conference
Newsroom
Press releases
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED
09/11/17 - 14:15
Investors
Information Documents
Growth in revenues, profitability and net profit in 2017. Proposed ordinary dividend of € 0.85 per share and special dividend of € 1.80 per share
Press releases
Growth in revenues, profitability and net profit in 2018
14/03/19 - 14:16
Investors
Presentation
H1 2008 Results Presentation
08/08/08
Investors
Presentation
H1 2009 Results Presentation
06/08/09
Investors
Presentation
H1 2010 Results Presentation
06/08/10
Investors
Presentation
H1 2011 Results Presentation
03/08/11
Investors
Presentation
H1 2012 Results Presentation
08/08/12
Investors
Presentation
H1 2013 Results Presentation
01/08/13
Investors
Presentation
H1 2014 Results Presentation
01/08/14
Investors
Presentation
H1 2015 Results Presentation
30/07/15
Investors
Presentation
H1 2016 Results Presentation
04/08/16
Investors
Presentation
H1 2017 Results Presentation
03/08/17
Investors
Presentation
H1 2018 Results Presentation
02/08/18
Investors
Results
H1 2018 Results Presentation
Investors
Presentation
H1 2019 Results Presentation
31/07/19
Investors
Results
H1 2019 Results Presentation
Investors
Presentation
H1 2020 Results Presentation
30/07/20
Investors
Results
H1 2020 Results Presentation
Investors
Presentation
H1 2021 Results Presentation
30/07/21
Investors
Results
H1 2021 Results Presentation
Investors
Presentation
H1 2022 Results Presentation
03/08/22
Investors
Results
H1 2022 Results Presentation
Investors
Presentation
H1 2023 Results Presentation
27/07/23
Investors
Shareholders' meeting
Half-Year Financial Report at June 30, 2017
27/04/17 - 14:00
About Diasorin
Shareholders' meeting
Half-Year Financial Report at June 30, 2019
24/04/19 - 14:00
About Diasorin
Shareholders' meeting
Half-Year Financial Report at June 30, 2020
10/06/20 - 14:00
About Diasorin
Annual and Interim Reports
Half-Year Financial Report at June 30, 2024
06/08/24
Immunodiagnostics
Press releases
Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only)
02/04/12 - 2:00
Investors
Immunodiagnostics product
LIAISON® Herpes Simplex Virus (HSV) Diagnostic Solution
Immunodiagnostics
Coverage
HSBC
Investors
Press releases
IgG test to detect immune response to SARS-CoV-2
07/04/20 - 7:14
Investors
Image gallery
Immunodiagnostics LIAISON® XL_FRONT
Newsroom
Image gallery
Immunodiagnostics LIAISON® XS_FRONT
Newsroom
Information Documents
Information Document pursuant art. 71 of the Issuers' Regulation - Acquisition of Luminex Corporation
Coverage
INTERMONTE
Investors
Coverage
INVEST SECURITIES
Investors
Events
Invitation to conf call on Focus Diagnostics Products Business Acquisition
Newsroom
Information Documents
Invitation to conf call on Focus Diagnostics Products Business Acquisition
Press releases
Issuance of the "Physical Settlement Notice"
27/10/21 - 16:35
Investors
Coverage
JEFFERIES
Investors
Coverage
KEPLER CHEUVREUX
Investors
Immunodiagnostics product
LIAISON® Adenovirus and Rotavirus Diagnostic Solution
Immunodiagnostics
Immunodiagnostics product
LIAISON® Bordetella pertussis Diagnostic Solution
Immunodiagnostics
Pagination
- First page
- 1
- 2
- 3
- 4
- Last page